REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Key Takeaways Replimune shares fell 54.2% in three months after the FDA issued a CRL against its RP1 BLA in July.The FDA cited shortcomings in the IGNYTE study data but noted no safety concerns with RP1.Replimune met with the FDA to discuss next steps, with a clear regulatory path still uncertain.Replimune Group’s (REPL) share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics license applicati ...